Abstract
The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrome (ARDS) is to restore the normal composition of the surfactant system, as well as to overcome ongoing inactivation of present surfactant. Indeed, surfactant replacement therapy can normalize the composition of the surfactant system and restore its surface activity, which results in restoration of the gas exchange. Several phase II- and phase III-studies have been performed to investigate safety and efficacy of surfactant replacement therapy in patients with ARDS. In this manuscript we will discuss the differences in the composition of exogenous surfactant, the diverse modes of delivery of surfactant, and timing of therapy, in relation to the efficacy of surfactant instillation in several published and yet unpublished studies.
Keywords: Additive Drug, ARDS-Patients, exogenous surfactant
Current Drug Targets
Title: Is Surfactant a Promising Additive Drug in ALI / ARDS-Patients?
Volume: 5 Issue: 5
Author(s): Marcus J. Schultz and Jozef Kesecioglu
Affiliation:
Keywords: Additive Drug, ARDS-Patients, exogenous surfactant
Abstract: The rationale for surfactant replacement therapy in patients with acute respiratory distress syndrome (ARDS) is to restore the normal composition of the surfactant system, as well as to overcome ongoing inactivation of present surfactant. Indeed, surfactant replacement therapy can normalize the composition of the surfactant system and restore its surface activity, which results in restoration of the gas exchange. Several phase II- and phase III-studies have been performed to investigate safety and efficacy of surfactant replacement therapy in patients with ARDS. In this manuscript we will discuss the differences in the composition of exogenous surfactant, the diverse modes of delivery of surfactant, and timing of therapy, in relation to the efficacy of surfactant instillation in several published and yet unpublished studies.
Export Options
About this article
Cite this article as:
Schultz J. Marcus and Kesecioglu Jozef, Is Surfactant a Promising Additive Drug in ALI / ARDS-Patients?, Current Drug Targets 2004; 5 (5) . https://dx.doi.org/10.2174/1389450043345399
DOI https://dx.doi.org/10.2174/1389450043345399 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments of Quinoline Derivatives and their Potential Biological Activities
Current Organic Synthesis Counter-regulatory ‘Renin-Angiotensin’ System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected Patients
Infectious Disorders - Drug Targets Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry IPC Synthase as a Useful Target for Antifungal Drugs
Current Drug Targets - Infectious Disorders Apoptotic Cell Death in Bronchopulmonary Dysplasia
Current Pediatric Reviews Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design A Facile, Efficient and Chemoseletive Deprotection of Silyl Ethers Using Zinc (II) Trifluoromethanesulfonate
Letters in Organic Chemistry Non-Peptidic HIV Protease Inhibitors
Current Topics in Medicinal Chemistry Editorial from Editor-in-Chief: Flipping and Cooling in Severe Hypoxemia: An Example of Combination Therapy in Respiratory Medicine
Current Respiratory Medicine Reviews Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail
Infectious Disorders - Drug Targets Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk
Current Medicinal Chemistry COVID-19 and Diabetes: will Novel Drugs for Diabetes Help in COVID-19?
Current Molecular Pharmacology Evaluation of the Superabsorbent Effect on the Yield and Some Growth Factors of Pisum sativum L. under Drought Stress Conditions
Recent Patents on Food, Nutrition & Agriculture Antibacterial Activity of Lipophilic Fluoroquinolone Derivatives
Medicinal Chemistry Machine Learning in Discovery of New Antivirals and Optimization of Viral Infections Therapy
Current Medicinal Chemistry N-Acetyl Cysteine Attenuates the Sarcopenia and Muscle Apoptosis Induced by Chronic Liver Disease
Current Molecular Medicine Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Mechanical Engineering